Cai-Cun Zhou (Caicun Zhou)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 10

Top Venues

Nature cancer

Cancer medicine

International journal of cancer

Canadian respiratory journal

This page only lists publications with an associated author ORCID identifier.

Publications

Cai-Cun Zhou, Ziping Wang, Meili Sun, Lejie Cao, Zhiyong Ma, Rong Wu, Yan Yu, Wenxiu Yao, Si Sun, Jianhua Chen, Wu Zhuang, Jiuwei Cui, Xueqin Chen, You Lu, Hong Shen, Chunhong Hu, Jiwei Liu, Yunpeng Liu, Mengzhao Wang, Xingya Li, Ping Sun, Yongqian Shu, Jianying Zhou, Jingzhang Li, Kangsheng Gu, Changli Wang, Hui Zhao, Yiping Zhang, Chunling Liu, Jingru Wang, Rumei Chen, Mengmeng Qin, Hao Wang, Jason Yang
Author Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC. Nature cancer (2024)
Cai-Cun Zhou, Ziping Wang, Meili Sun, Lejie Cao, Zhiyong Ma, Rong Wu, Yan Yu, Wenxiu Yao, Si Sun, Jianhua Chen, Wu Zhuang, Jiuwei Cui, Xueqin Chen, You Lu, Hong Shen, Chunhong Hu, Jiwei Liu, Yunpeng Liu, Mengzhao Wang, Xingya Li, Ping Sun, Yongqian Shu, Jianying Zhou, Jingzhang Li, Kangsheng Gu, Changli Wang, Hui Zhao, Yiping Zhang, Chunling Liu, Jingru Wang, Rumei Chen, Mengmeng Qin, Hao Wang, Jason Yang
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC. Nature cancer (2023)
Dingzhi Huang, Cai-Cun Zhou, Gisoo Barnes, Yiyuan Ma, Songzi Li, Lin Zhan, Boxiong Tang
The effects of tislelizumab treatment on the health-related quality of life of patients with advanced non-small cell lung cancer. Cancer medicine (2023)
Shengxiang Ren, Jifeng Feng, Shenglin Ma, HuaJun Chen, Zhiyong Ma, Cheng Huang, Li Zhang, Jianxing He, Changli Wang, Jianying Zhou, Pongwut Danchaivijtr, Chin-Chou Wang, Ihor Vynnychenko, Kai Wang, Francisco Orlandi, Virote Sriuranpong, Ben Li, Jun Ge, Thao Dang, Cai-Cun Zhou
KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC. International journal of cancer (2023)
Tao Jiang, Qiqi Jin, Jiahao Wang, Feng-Ying Wu, Jian Chen, Gongyan Chen, Yunchao Huang, Jianhua Chen, Ying Cheng, Qi-Ming Wang, Yue-Yin Pan, Jian-Ying Zhou, Jianhua Shi, Xingxiang Xu, LiZhu Lin, Wei Zhang, Yiping Zhang, Yun-Peng Liu, Yong Fang, Jifeng Feng, Zhehai Wang, Sheng Hu, Jian Fang, Yongqian Shu, Jiu-Wei Cui, Yi Hu, Wenxiu Yao, Xingya Li, Xiaoyan Lin, Rui Wang, Yongsheng Wang, Wei Shi, Gaohua Feng, Jun Ni, Beibei Mao, Dandan Ren, Huaibo Sun, Henghui Zhang, Luo-Nan Chen, Cai-Cun Zhou, Shengxiang Ren
HLA-I evolutionary divergence confers response to PD-1 blockade plus chemotherapy in untreated advanced non-small-cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Weigang Xiu, Jincheng Zheng, Yuwen Zhou, He Du, Jiayu Li, Wei Li, Caicun Zhou, Cai-Cun Zhou, Feng-Ying Wu
A nomogram for the prediction of the survival of patients with advanced non-small cell lung cancer and interstitial lung disease. Cancer medicine (2023)
Shengxiang Ren, Jifeng Feng, Shenglin Ma, HuaJun Chen, Zhiyong Ma, Cheng Huang, Li Zhang, Jianxing He, Changli Wang, Jianying Zhou, Pongwut Danchaivijtr, Chin-Chou Wang, Ihor Vynnychenko, Kai Wang, Francisco Orlandi, Virote Sriuranpong, Ben Li, Jun Ge, Thao Dang, Cai-Cun Zhou
KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC. International journal of cancer (2023)
Yuan-Kai Shi, Lin Wu, Xinmin Yu, Puyuan Xing, Yan Wang, Jianying Zhou, Airong Wang, Jianhua Shi, Yi Hu, Ziping Wang, Guangyu An, Yong Fang, Sanyuan Sun, Cai-Cun Zhou, Changli Wang, Feng Ye, Xingya Li, Junye Wang, Mengzhao Wang, Yunpeng Liu, Yanqiu Zhao, Ying Yuan, Jifeng Feng, Zhendong Chen, Jindong Shi, Tao Sun, Gang Wu, Yongqian Shu, Qisen Guo, Yi Zhang, Yong Song, Shucai Zhang, Yuan Chen, Wei Li, Hongrui Niu, Wenwei Hu, Lijun Wang, Jianan Huang, Yang Zhang, Ying Cheng, Zhengdong Wu, Bo Peng, Jiya Sun, Christoph Mancao, Yanqi Wang, Luyao Sun
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3). Cancer communications (London, England) (2022)
Fengying Wu, Jue Fan, Yayi He, Anwen Xiong, Jia Yu, Yixin Li, Yan Zhang, Wencheng Zhao, Fei Zhou, Wei Li, Jie Zhang, Xiaosheng Zhang, Meng Qiao, Guanghui Gao, Shanhao Chen, Xiaoxia Chen, Xuefei Li, Likun Hou, Chunyan Wu, Chunxia Su, Shengxiang Ren, Margarete Odenthal, Reinhard Buttner, Nan Fang, Cai-Cun Zhou
Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nature communications 12 (1) (2021)
Su-Gang Gong, Lan Wang, Bigyan Pudasaini, Ping Yuan, Rong Jiang, Qin-Hua Zhao, Jing He, Rui Zhang, Wen-Hui Wu, Jin-Ming Liu, Cai-Cun Zhou
Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study. Canadian respiratory journal 2018 (2018)

Cai-Cun Zhou.css-eqlu8i{font-size:small;padding-left:4px;} (Caicun Zhou)

Publication Activity (10 Years)

Top Topics

Top Venues

Cai-Cun Zhou (Caicun Zhou)